» Articles » PMID: 1554974

Ocular Carteolol. A Review of Its Pharmacological Properties, and Therapeutic Use in Glaucoma and Ocular Hypertension

Overview
Journal Drugs Aging
Specialties Geriatrics
Pharmacology
Date 1992 Jan 1
PMID 1554974
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Carteolol is a relatively potent nonselective beta-adrenoceptor antagonist with partial agonist activity. It is used topically to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Twice-daily ocular administration of carteolol 1 or 2% lowers IOP by approximately 32% on average in patients with these conditions, an efficacy equivalent to that of timolol 0.25 or 0.5%. Carteolol eyedrops lack local anaesthetic activity, appear to cause less local irritation than timolol, and produce less pronounced decreases in heart rate or dyspnoea, possibly due to partial agonist activity. The latter activity may also improve retinal perfusion. Thus, although additional comparative trials are needed to accurately assess the precise place of carteolol in therapy, this drug offers a useful alternative to timolol in the management of conditions associated with a raised IOP, and may have advantages in older patients with regard to its tolerability profile, although careful monitoring is still wise.

Citing Articles

Adrenoceptors in the Eye - Physiological and Pathophysiological Relevance.

Ruan Y, Buonfiglio F, Gericke A Handb Exp Pharmacol. 2023; 285:453-505.

PMID: 38082203 DOI: 10.1007/164_2023_702.


Ophthalmological features and treatments in five cases of Waardenburg syndrome.

Liu Y, Pan H, Wang J, Yao Q, Lin M, Ma B Exp Ther Med. 2020; 20(4):3072-3077.

PMID: 32855674 PMC: 7444341. DOI: 10.3892/etm.2020.9035.


Carteolol hydrochloride suppresses the generation of reactive oxygen species and rescues cell death after ultraviolet irradiation of cultured lens epithelial cells.

Kaji Y, Kiuchi T, Oshika T Open Ophthalmol J. 2011; 4:60-5.

PMID: 21283534 PMC: 3031156. DOI: 10.2174/1874364101004010060.


Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension.

Henness S, Swainston Harrison T, Keating G Drugs Aging. 2007; 24(6):509-28.

PMID: 17571916 DOI: 10.2165/00002512-200724060-00007.


Pharmacological therapy for glaucoma: a review.

Hoyng P, van Beek L Drugs. 2000; 59(3):411-34.

PMID: 10776828 DOI: 10.2165/00003495-200059030-00003.


References
1.
Collignon-Brach J . Early visual field changes with beta-blocking agents. Surv Ophthalmol. 1989; 33 Suppl:429-30; discussion 435-6. DOI: 10.1016/0039-6257(89)90073-8. View

2.
Duff G, Graham P . A double-crossover trial comparing the effects of topical carteolol and placebo on intraocular pressure. Br J Ophthalmol. 1988; 72(1):27-8. PMC: 1041361. DOI: 10.1136/bjo.72.1.27. View

3.
Duff G . A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. Acta Ophthalmol (Copenh). 1987; 65(5):618-21. DOI: 10.1111/j.1755-3768.1987.tb07052.x. View

4.
Kitazawa Y, Azuma I, Takase M, Komemushi S . [Ocular hypotensive effects of carteolol hydrochloride in primary open-angle glaucoma and ocular hypertensive patients. A double-masked cross-over study for the determination of concentrations optimal for the clinical use (author's transl)]. Nippon Ganka Gakkai Zasshi. 1981; 85(7):798-804. View

5.
Gerber S, Cantor L, Brater D . Systemic drug interactions with topical glaucoma medications. Surv Ophthalmol. 1990; 35(3):205-18. DOI: 10.1016/0039-6257(90)90090-i. View